Vehicles are doing a better job of protecting people in crashes, but a new crop of advanced technology aims to prevent many crashes from happening altogether. A new study by the Highway Loss Data Institute (HLDI) finds that one kind of advanced forward collision avoidance system is working to prevent about a quarter of the common low-speed crashes that happen in everyday commuter traffic.
The study of insurance claims found that Volvo XC60 midsize SUVs outfitted with a standard collision avoidance feature called City Safety are far less likely to be involved in low-speed crashes than comparable vehicles without the system. City Safety is designed to help a driver avoid rear-ending another vehicle in slow-moving, heavy traffic. Claims under property damage liability coverage — the insurance that pays for damage to vehicles that an at-fault driver hits — were filed 27 percent less often for the XC60 than other midsize luxury SUVs.
For more information: www.iihs.org
When it comes to their health, nearly 90 percent of Americans lack the literacy skills to understand basic medical information and instruction. Low literacy has been linked to poor health outcomes such as higher rates of hospitalization and less frequent use of preventive services. A few quick minutes with a physician is not sufficient for most of us to understand a complex or chronic medical condition and how we can manage it. But new research indicates that video storytelling can be an effective way to educate people about health conditions - and watching others share their health stories can empower people to take control of their own health.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/besmartbewell/50819/
For those in the creative fields, anticipating and adapting to change -- from the tools they’re using at work to the people they’re interacting with to the audiences they’re targeting -- has become part and parcel of the job. A new research guide, The Creative Team of the Future, explores key trends shaping the marketing and design fields, and how industry professionals can prepare for and capitalize on upcoming changes.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/roberthalf/50678/
New data revealed that nearly 100 percent (99%) of 200 U.S. primary care physicians surveyed agree that heart disease and stroke are the number one cause of death and disability among type 2 diabetes patients; however, almost 40 percent (36%) of these physicians underestimate the number of patients who die from cardiovascular disease. Furthermore, while people with diabetes are two to four times more likely to have heart disease than people without diabetes, the survey, conducted by Harris Interactive and supported by Merck, found only one out of five (21%) patients (n=664) listed heart attack or heart failure as their biggest worry regarding diabetes complications, and even fewer patients (7%) listed stroke.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/merck/50638/
Released today, The Aging Myth is an explosive new book by noted scientist and anti-aging researcher Joseph Chang, Ph.D., that reveals how new genetic discoveries are challenging traditional anti-aging philosophies and helping people live younger longer. In The Aging Myth, Dr. Chang uses a conversational and accessible style to dispel common myths about aging and explains some of the latest groundbreaking research in the field.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/nuskin/50881/
From cost-reduction strategies to green cleaning products and expertise, xpedx® will promote a variety of products and services specifically designed for property and facility managers during the 2011 BOMA International Conference & The Every Building Show® June 26-28.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/xpedx/50817/
With each generation comes a new style and a new language. It’s as unique as a fingerprint and can be seen everywhere from pop culture to the greeting card aisle. Enter justWink, a new greeting card line from American Greetings (NYSE: AM) which offers the next generation of greeting card shoppers something completely new and unexpected that also connects cards with the mobile world for the first time with a free greeting app for iPhone and Android users. Something for the person who values their personal style, a great (if sometimes offbeat) sense of humor, and who is dedicated to keeping in touch with all of the important people in their lives. Something designed precisely for right this very now.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/americangreetings/48735/
An international team of researchers led by Gerard D. Schellenberg, PhD, a member of the CurePSP Genetics Consortium and professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania, has identified three new genes that can increase the risk of people developing Progressive Supranuclear Palsy (PSP).
PSP is a rare neurodegenerative brain disease, similar to Parkinson’s disease, which causes severe disability by destroying parts of cells that allow the brain to function normally. While PSP has underlying biological similarities to Alzheimer’s disease, a disease which primarily affects memory, PSP impacts a person’s physical movement and bodily functions. PSP leads to progressive decline in patients — there is no known cause or cure.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/psp/49958/
Rising food prices are causing poor children and families in developing countries to sink deeper into hunger and malnutrition, according to Children International, a leading U.S.-based humanitarian organization.
According to the Food and Agriculture Organization, 925 million people around the world go hungry each day compared to 848 million in 2007. Experts blame the high cost of gasoline and diesel fuel as a main cause for the spike in food prices globally. As gas prices soared in 2010, food prices have risen with the same speed, leaving poor families helped by Children International with few options. Most poor parents work long hours for little pay and lack the money needed to purchase food and cook a nutritious meal.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/childreninternational/46389/
According to Congress’ “Don’t Let the Bed Bugs Bite” Act of 2009, bed bug populations have grown by 500 percent in the United States in recent years, primarily due to increased travel and antique merchandise. Bed bugs are creepy, crawly and hard to kill – an emotional topic that literally and figuratively keeps people up at night. Becoming educated on the bug, its habits, detecting, treating and preventing an infestation is an effective first step to control. Luckily, there is a solution: Ortho Home Defense Max BEDBUG Killer. Take back your bed and keep the critters from turning bedtime into bite time.
To view Multimedia News Release, go to http://www.multivu.com/players/English/47692-Ortho-Home-Defense-Max-BEDBUG-Killer/
Belfast is set to mark the 100th anniversary of the launch of one of the city’s most famous creations – RMS Titanic. On May 31st 1911, Titanic was launched into Belfast Lough by Harland & Wolff – then the largest shipyard in the world. It took three years to build and just 62 seconds to complete the launch.
To mark the occasion, there will be a special slipway event attended by the Lord Mayor of Belfast, dignitaries of Cherbourg and Titanic societies to reflect Belfast’s maritime heritage. There will also be a flare set-off to mark the moment exactly 100 years ago when the Titanic was launched.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/tourismireland/48926/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
